JP2016029060A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016029060A5 JP2016029060A5 JP2015181443A JP2015181443A JP2016029060A5 JP 2016029060 A5 JP2016029060 A5 JP 2016029060A5 JP 2015181443 A JP2015181443 A JP 2015181443A JP 2015181443 A JP2015181443 A JP 2015181443A JP 2016029060 A5 JP2016029060 A5 JP 2016029060A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- liquid composition
- adalimumab
- cathepsin
- rfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 31
- 239000007788 liquid Substances 0.000 claims 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 15
- 108010007562 Adalimumab Proteins 0.000 claims 11
- 229960002964 adalimumab Drugs 0.000 claims 11
- 102000004172 Cathepsin L Human genes 0.000 claims 9
- 108090000624 Cathepsin L Proteins 0.000 claims 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000002335 preservative Effects 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 5
- 239000000600 sorbitol Substances 0.000 claims 5
- 238000003367 kinetic assay Methods 0.000 claims 3
- 238000007865 diluting Methods 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 229960000633 Dextran Sulfate Drugs 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 229940071643 Prefilled Syringe Drugs 0.000 claims 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical group C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Claims (27)
- アダリムマブ、およびソルビトール、糖、グリセロールまたは防腐剤のいずれかを含む液状医薬組成物であって、
アダリムマブはチャイニーズハムスター卵巣(CHO)細胞発現系で発現され、
前記組成物は、カテプシンL速度論アッセイによりアッセイするとき、1.5RFU/秒/mgアダリムマブ未満のカテプシンL活性のレベルが観察されることを特徴とし、
前記カテプシンL速度論アッセイが、
i)ポリスチレン容器中で前記組成物を25mM NaOAc、5mM DTT及び1mM EDTA、pH5.5中に希釈すること、
ii)デキストラン硫酸を0.035μg/mlの濃度まで加え、37℃で6時間インキュベートすること、
iii)C末端で蛍光性7−アミノ−4−メチルクマリンに共有結合したZ−ロイシン−アルギニン(Z−ロイシン−アルギニン−AMC)を加えること、ここで、希釈、添加及びインキュベートの工程が、Z−ロイシン−アルギニン−AMCのカテプシンLによる加水分解の測定を直線範囲内で可能にするのに十分であること、及び
iv)RFU/秒/mgアダリムマブの直線範囲内でZ−ロイシン−アルギニン−AMC加水分解を測定すること
を含む、液状医薬組成物。 - 予め充填された注射器に包装された、請求項1に記載の液状組成物。
- 50mg/mLのアダリムマブを含む、請求項2に記載の液状組成物。
- 皮下注射に好適な、請求項3に記載の液状組成物。
- ソルビトールを含む、請求項4に記載の液状組成物。
- グリセロールを含む、請求項4に記載の液状組成物。
- 糖を含む、請求項4に記載の液状組成物。
- 防腐剤を含む、請求項4に記載の液状組成物。
- カテプシンL活性が1.3RFU/秒/mgアダリムマブ以下である、請求項1に記載の液状組成物。
- ソルビトールを含む、請求項9に記載の液状組成物。
- グリセロールを含む、請求項9に記載の液状組成物。
- 糖を含む、請求項9に記載の液状組成物。
- 防腐剤を含む、請求項9に記載の液状組成物。
- カテプシンL活性が1.0RFU/秒/mgアダリムマブ以下である、請求項9に記載の液状組成物。
- ソルビトールを含む、請求項14に記載の液状組成物。
- グリセロールを含む、請求項14に記載の液状組成物。
- 糖を含む、請求項14に記載の液状組成物。
- 防腐剤を含む、請求項14に記載の液状組成物。
- カテプシンL活性が0.6RFU/秒/mgアダリムマブ以下である、請求項1に記載の液状組成物。
- ソルビトールを含む、請求項19に記載の液状組成物。
- グリセロールを含む、請求項19に記載の液状組成物。
- 糖を含む、請求項19に記載の液状組成物。
- 防腐剤を含む、請求項19に記載の液状組成物。
- カテプシンL活性が0.85RFU/秒/mgアダリムマブ以下である、請求項1に記載の液状組成物。
- 稀釈された組成物が20μg/mLのアダリムマブ濃度を有する、請求項1から24のいずれか一項に記載の液状組成物。
- 稀釈された組成物が50μg/mLのアダリムマブ濃度を有する、請求項1から24のいずれか一項に記載の液状組成物。
- カテプシンL速度論アッセイのi)が前記組成物を600倍に希釈することを含む、請求項1から26のいずれか一項に記載の液状組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78972506P | 2006-04-05 | 2006-04-05 | |
US60/789,725 | 2006-04-05 | ||
US79041406P | 2006-04-06 | 2006-04-06 | |
US60/790,414 | 2006-04-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012255474A Division JP5813618B2 (ja) | 2006-04-05 | 2012-11-21 | 抗体精製 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016029060A JP2016029060A (ja) | 2016-03-03 |
JP2016029060A5 true JP2016029060A5 (ja) | 2016-04-14 |
JP5994004B2 JP5994004B2 (ja) | 2016-09-21 |
Family
ID=38581592
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009504272A Withdrawn JP2009532474A (ja) | 2006-04-05 | 2007-04-04 | 抗体精製 |
JP2012255474A Active JP5813618B2 (ja) | 2006-04-05 | 2012-11-21 | 抗体精製 |
JP2013252725A Active JP5997128B2 (ja) | 2006-04-05 | 2013-12-06 | 抗体精製 |
JP2015143625A Active JP5947427B2 (ja) | 2006-04-05 | 2015-07-21 | 抗体精製 |
JP2015181443A Active JP5994004B2 (ja) | 2006-04-05 | 2015-09-15 | 抗体精製 |
JP2016163422A Active JP6367277B2 (ja) | 2006-04-05 | 2016-08-24 | 抗体精製 |
JP2018126553A Pending JP2018172416A (ja) | 2006-04-05 | 2018-07-03 | 抗体精製 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009504272A Withdrawn JP2009532474A (ja) | 2006-04-05 | 2007-04-04 | 抗体精製 |
JP2012255474A Active JP5813618B2 (ja) | 2006-04-05 | 2012-11-21 | 抗体精製 |
JP2013252725A Active JP5997128B2 (ja) | 2006-04-05 | 2013-12-06 | 抗体精製 |
JP2015143625A Active JP5947427B2 (ja) | 2006-04-05 | 2015-07-21 | 抗体精製 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016163422A Active JP6367277B2 (ja) | 2006-04-05 | 2016-08-24 | 抗体精製 |
JP2018126553A Pending JP2018172416A (ja) | 2006-04-05 | 2018-07-03 | 抗体精製 |
Country Status (16)
Country | Link |
---|---|
US (17) | US7863426B2 (ja) |
EP (4) | EP2738179A1 (ja) |
JP (7) | JP2009532474A (ja) |
KR (4) | KR20150064254A (ja) |
CN (4) | CN103509116A (ja) |
AU (1) | AU2007235484B2 (ja) |
BR (1) | BRPI0709726A2 (ja) |
CA (2) | CA2647029A1 (ja) |
IL (1) | IL194236A (ja) |
MX (1) | MX2008012896A (ja) |
NZ (4) | NZ596517A (ja) |
RU (2) | RU2466740C2 (ja) |
SG (2) | SG10201406358SA (ja) |
TW (2) | TWI392684B (ja) |
WO (1) | WO2007117490A2 (ja) |
ZA (1) | ZA200808372B (ja) |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DE122004000004I1 (de) * | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
CN102764436A (zh) * | 2002-07-19 | 2012-11-07 | 艾博特生物技术有限公司 | TNF α相关疾病的治疗 |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
TWI556829B (zh) | 2004-04-09 | 2016-11-11 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
TWI399384B (zh) | 2005-05-16 | 2013-06-21 | Abbott Biotech Ltd | TNFα抑制劑於治療侵蝕型多發性關節炎之用途 |
CN101663048A (zh) | 2005-11-01 | 2010-03-03 | 艾博特生物技术有限公司 | 使用生物标志物诊断强直性脊柱炎的方法和组合物 |
US20100190210A1 (en) * | 2006-03-20 | 2010-07-29 | Medarex, Inc. | Protein Purification |
KR20150064254A (ko) | 2006-04-05 | 2015-06-10 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2012586A4 (en) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
EP2010214A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
TWI542374B (zh) * | 2006-06-30 | 2016-07-21 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
KR20150002896A (ko) * | 2006-10-27 | 2015-01-07 | 애브비 바이오테크놀로지 리미티드 | 결정형 항-hTNF알파 항체 |
EP2679995A1 (en) * | 2007-05-31 | 2014-01-01 | AbbVie Inc. | Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
CN101980722A (zh) | 2007-08-08 | 2011-02-23 | 雅培制药有限公司 | 结晶抗体的组合物和方法 |
EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
KR20150008503A (ko) | 2007-10-30 | 2015-01-22 | 제넨테크, 인크. | 양이온 교환 크로마토그래피에 의한 항체 정제 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CN101969971A (zh) | 2007-11-30 | 2011-02-09 | 雅培制药有限公司 | 蛋白制剂及其制备方法 |
WO2009086550A1 (en) * | 2008-01-03 | 2009-07-09 | Abbott Laboratories | Predicting long-term efficacy of a compound in the treatment of psoriasis |
CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
CN107551270A (zh) | 2008-04-11 | 2018-01-09 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
BRPI0822510B8 (pt) * | 2008-04-30 | 2021-05-25 | Shanghai Zerun Biotech Co Ltd | método de preparação e uso de proteínas de lise de células vero, e kit de ensaio para a determinação de hcps de células vero. |
GB0818228D0 (en) * | 2008-10-06 | 2008-11-12 | Avecia Biolog Ltd | Purification process |
CN105111309A (zh) | 2008-10-20 | 2015-12-02 | Abbvie公司 | 使用a蛋白亲和层析分离和纯化抗体 |
BRPI0920572A8 (pt) | 2008-10-20 | 2015-10-27 | Abbott Lab | Inativação viral durante a purificação dos anticorpos |
MX2011004198A (es) * | 2008-10-20 | 2011-05-24 | Abbott Lab | Anticerpos que unen a il-12 y metodos para purificar los mismos. |
EP2346901A1 (en) * | 2008-10-20 | 2011-07-27 | Abbott Laboratories | Antibodies that bind to il-18 and methods of purifying the same |
AU2009331897A1 (en) | 2008-12-22 | 2010-07-01 | F. Hoffmann-La Roche Ag | Immunoglobulin purification |
US20120135005A1 (en) * | 2009-04-16 | 2012-05-31 | Harding Fiona A | ANTI-TNF-a ANTIBODIES AND THEIR USES |
EP2424594A4 (en) * | 2009-04-29 | 2014-12-24 | Abbvie Biotechnology Ltd | AUTOMATIC INJECTION DEVICE |
RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
EP2456789A1 (en) * | 2009-07-24 | 2012-05-30 | F. Hoffmann-La Roche AG | Optimizing the production of antibodies |
WO2011015922A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant tnk-tpa (tenecteplase) |
WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
HUE053489T2 (hu) | 2009-10-20 | 2021-06-28 | Abbvie Inc | Az anti-il-13 antitestek izolálása és tisztítása a protein A affinitás kromatográviával |
NZ600069A (en) * | 2009-12-15 | 2015-02-27 | Abbvie Biotechnology Ltd | Improved firing button for automatic injection device |
ES2796829T3 (es) | 2009-12-18 | 2020-11-30 | Csl Ltd | Procedimiento de purificación de polipéptidos |
IT1397061B1 (it) * | 2009-12-28 | 2012-12-28 | Kedrion Spa | Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale. |
WO2011090719A2 (en) | 2009-12-29 | 2011-07-28 | Dr. Reddy's Laboratories Ltd. | Protein purification by ion exchange |
BR112012020254A2 (pt) * | 2010-02-12 | 2016-05-03 | Dsm Ip Assets Bv | método para a purificação de anticorpos a partir de uma mistura de proteína e, unidade operacional única. |
FR2958936A1 (fr) * | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
NZ702172A (en) | 2010-04-21 | 2016-03-31 | Abbvie Biotechnology Ltd | Wearable automatic injection device for controlled delivery of therapeutic agents |
WO2011146179A2 (en) * | 2010-05-18 | 2011-11-24 | Abbott Laboratories | Apparatus and process of purification of proteins |
PT2575884T (pt) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Utilizações e composições para o tratamento de hidradenite supurativa (hs) |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
KR20150023923A (ko) | 2010-07-30 | 2015-03-05 | 이엠디 밀리포어 코포레이션 | 크로마토그래피 매질 및 방법 |
AU2011316730B2 (en) * | 2010-10-11 | 2015-12-10 | Abbvie Bahamas Ltd. | Processes for purification of proteins |
DK2637690T3 (da) | 2010-11-11 | 2017-01-02 | Abbvie Biotechnology Ltd | Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
WO2012082933A1 (en) * | 2010-12-15 | 2012-06-21 | Baxter International, Inc. | Eluate collection using conductivity gradient |
BR112013012422A2 (pt) * | 2010-12-21 | 2016-08-30 | Hoffmann La Roche | "método para produzir uma preparação de anticorpo e anticorpo anti-her2" |
CA2824454C (en) | 2011-01-24 | 2018-10-23 | Abbvie Biotechnology Ltd. | Removal of needle shields from syringes and automatic injection devices |
AU2012210170B2 (en) | 2011-01-24 | 2016-09-29 | Elcam Medical Agricultural Cooperative Association Ltd. | Injector |
JP6478214B2 (ja) | 2011-01-24 | 2019-03-06 | アッヴィ バイオテクノロジー リミテッド | オーバーモールド把持面を有する自動注射器 |
KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
US20120238730A1 (en) * | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US8911992B2 (en) | 2011-04-28 | 2014-12-16 | Bio-Rad Laboratories, Inc. | DNA removal in target molecule purification |
JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
WO2012160536A1 (en) * | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
EP2714713B1 (en) * | 2011-05-26 | 2018-05-09 | Dr. Reddy's Laboratories Limited | Purification of anti-cd20 antibodies |
EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
US20140288278A1 (en) * | 2011-10-31 | 2014-09-25 | Joseph Nti-Gyabaah | Chromatography process for resolving heterogeneous antibody aggregates |
PT2791176T (pt) * | 2011-12-15 | 2018-11-05 | Prestige Biopharma Pte Ltd | Um método de purificação de anticorpos |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
SG11201407809QA (en) | 2012-05-31 | 2014-12-30 | Agency Science Tech & Res | Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities |
CN102757496B (zh) * | 2012-06-07 | 2014-06-18 | 山东泉港药业有限公司 | 一种抗vegf抗体片段的纯化制备方法 |
LT2864346T (lt) * | 2012-06-21 | 2019-01-25 | Synthon Biopharmaceuticals B.V. | Antikūnų gryninimo metodas |
CA2883272A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
JP6326066B2 (ja) * | 2012-12-20 | 2018-05-16 | メディミューン,エルエルシー | 凝集プロファイルが改善されている液状抗体製剤 |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
WO2014151901A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Improvement of mammalian cell culture performance through surfactant supplementation of feed media |
AU2014240431A1 (en) | 2013-03-14 | 2015-08-27 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
WO2014158231A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) * | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
CA2909969A1 (en) * | 2013-05-13 | 2014-12-31 | Medimmune, Llc | Separation of recombinant polyclonal antibody multimers with minimal separation of monomers |
TWI596107B (zh) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
EP3035903B1 (en) | 2013-08-20 | 2018-08-22 | Anutra Medical, Inc. | Syringe fill system and method |
JP2016530271A (ja) * | 2013-08-23 | 2016-09-29 | ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 細胞の破砕及び/又は生体分子の回収のための微粒子 |
KR102373930B1 (ko) | 2013-09-13 | 2022-03-11 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
JP6546178B2 (ja) | 2013-09-13 | 2019-07-17 | ジェネンテック, インコーポレイテッド | 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法 |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
WO2015057910A1 (en) | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3110829A4 (en) * | 2014-02-27 | 2017-10-11 | Agency for Science, Technology and Research | Antibody purification process |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
US20170183376A1 (en) | 2014-06-24 | 2017-06-29 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
WO2016004197A1 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
SG11201703399QA (en) | 2014-12-08 | 2017-05-30 | Emd Millipore Corp | Mixed bed ion exchange adsorber |
TW201809008A (zh) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
TWI808330B (zh) | 2014-12-19 | 2023-07-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
JP6699085B2 (ja) * | 2015-03-25 | 2020-05-27 | 東ソー株式会社 | Fc結合性タンパク質の精製方法 |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
CN105021824A (zh) * | 2015-07-06 | 2015-11-04 | 上海优者生物科技有限公司 | 用于定量检测生物医药制品中残留cho宿主细胞蛋白的elisa试剂盒及其使用方法 |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
US10519479B1 (en) * | 2016-03-15 | 2019-12-31 | Ares Trading S.A. | Methods for modifying glycosylation using manganese |
SG11201801024XA (en) | 2016-08-05 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Therapeutic or preventive compositions for il-8-related diseases |
KR102369014B1 (ko) | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
JP7058272B2 (ja) * | 2016-09-07 | 2022-04-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗体を精製するための方法 |
KR20230119729A (ko) | 2016-10-25 | 2023-08-16 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피 데이터 분석을 위한 방법 및 시스템 |
US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
JP7414529B2 (ja) | 2017-06-07 | 2024-01-16 | シファメド・ホールディングス・エルエルシー | 血管内流体移動デバイス、システム、および使用方法 |
KR101999818B1 (ko) * | 2017-07-26 | 2019-07-12 | ㈜로제타엑소좀 | 소수성 상호작용을 이용한 세포밖 소포체의 분리방법 |
WO2019044736A1 (ja) * | 2017-08-28 | 2019-03-07 | 静岡県公立大学法人 | コリバクチンおよびコリバクチン産生菌の検出方法および検出プローブ |
WO2019094963A1 (en) | 2017-11-13 | 2019-05-16 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
RU2680598C1 (ru) * | 2018-01-10 | 2019-02-25 | Федеральное казённое учреждение здравоохранения "Иркутский ордена Трудового Красного Знамени научно-исследовательский противочумный институт Сибири и Дальнего Востока" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ получения препаратов субклеточных фракций туляремийного микроба |
WO2019152875A1 (en) | 2018-02-01 | 2019-08-08 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
ES2914987T3 (es) * | 2018-04-20 | 2022-06-20 | Janssen Biotech Inc | Calificación de columnas de cromatografía en métodos de fabricación para producir composiciones de anticuerpos anti-IL12/IL23 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
WO2020112906A1 (en) * | 2018-11-26 | 2020-06-04 | North Carolina State University | Peptide ligands for capture of host cell proteiins |
US11576920B2 (en) | 2019-03-18 | 2023-02-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
EP4034192A4 (en) | 2019-09-25 | 2023-11-29 | Shifamed Holdings, LLC | INTRAVASCULAR BLOOD PUMP SYSTEMS AND METHODS OF USE AND CONTROL THEREOF |
CN111072758B (zh) * | 2019-12-28 | 2023-10-20 | 重庆艾力彼生物科技有限公司 | 铜绿假单胞菌疫苗重组蛋白reSBP的纯化方法 |
JP2023510595A (ja) * | 2020-01-17 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ウイルスクリアランスのための疎水性相互作用クロマトグラフィー |
KR102154952B1 (ko) * | 2020-02-21 | 2020-09-10 | 프레스티지바이오로직스 주식회사 | 아달리무맙의 Non-Protein A 정제방법 |
WO2021170060A1 (en) * | 2020-02-28 | 2021-09-02 | Wuxi Biologics (Shanghai) Co., Ltd. | Purification of bispeciifc antibodies |
BR112023018404A2 (pt) * | 2021-03-12 | 2023-11-28 | Excepgen Inc | Sistemas e métodos para expressão de proteína |
US11879043B2 (en) * | 2021-04-05 | 2024-01-23 | Dionex Corporation | Coated poly-olefins |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US496861A (en) | 1893-05-09 | Raising or lowering device for buggy-tops | ||
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
EP0609722A1 (en) | 1981-09-08 | 1994-08-10 | The Rockefeller University | An in vitro method for detecting the presence of invasive stimuli in mammals |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4534972A (en) | 1983-03-29 | 1985-08-13 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
IL73883A (en) | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
ATE114673T1 (de) | 1985-08-16 | 1994-12-15 | Univ Rockefeller | Modulator der anabolischen aktivität und seine verwendungen. |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
EP0230574A3 (en) | 1986-01-31 | 1989-03-22 | Yale University | Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
AU626572B2 (en) | 1988-07-18 | 1992-08-06 | Chiron Corporation | Monoclonal antibodies reactive with cachectin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
EP0366043B1 (en) | 1988-10-24 | 1994-03-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibody |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ATE147634T1 (de) | 1988-12-19 | 1997-02-15 | American Cyanamid Co | Produkte zur behandlung des endotoxin -schocks bei einem säugetier |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
EP0486526B2 (en) | 1989-08-07 | 2001-03-07 | Peptech Limited | Tumour necrosis factor binding ligands |
US6451983B2 (en) | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
GB8921123D0 (en) | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
DE4037604A1 (de) | 1990-04-25 | 1991-10-31 | Bayer Ag | Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5110913A (en) * | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB2279077B (en) | 1990-12-21 | 1995-06-14 | Celltech Ltd | Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
US20060246073A1 (en) | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US20040120952A1 (en) | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
CA2736076A1 (en) | 1991-03-18 | 1992-09-19 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US20070298040A1 (en) | 1991-03-18 | 2007-12-27 | Centocor, Inc. | Methods of treating seronegative arthropathy with anti-TNF antibodies |
DE69130262T2 (de) | 1991-03-29 | 1999-03-18 | Immunex Corp | Isolierte virale proteine als cytokinantagonisten |
AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
WO1993011793A1 (en) | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
DE69331265T2 (de) | 1992-04-02 | 2002-08-08 | Smithkline Beecham Corp | Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor |
ES2121907T3 (es) | 1992-08-28 | 1998-12-16 | Bayer Ag | Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas. |
NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
EP0671936A1 (en) | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
DE122009000074I1 (de) | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
DE4307508A1 (de) | 1993-03-10 | 1994-09-15 | Knoll Ag | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche) |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
NZ278607A (en) | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
JPH09509835A (ja) | 1994-03-04 | 1997-10-07 | メルク エンド カンパニー インコーポレーテッド | アラニン走査型突然変異誘発によるin vitro抗体アフィニティー成熟 |
ZA955642B (en) | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
IL122910A (en) | 1995-07-27 | 2002-05-23 | Genentech Inc | Stable isotonic protein formulation that has undergone lyophilization |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DE122004000004I1 (de) | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7086947B2 (en) * | 1997-07-01 | 2006-08-08 | Walker Digital, Llc | Systems and methods for facilitating play of a casino game via expiring prepaid plays of the casino game |
CN1305896C (zh) * | 1998-05-06 | 2007-03-21 | 基因技术股份有限公司 | 用离子交换层析纯化蛋白质 |
EP1308455B9 (en) | 1998-05-06 | 2006-06-14 | Genentech, Inc. | A composition comprising anti-HER2 antibodies |
AU3633000A (en) * | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
AU4314900A (en) | 1999-04-28 | 2000-11-17 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same |
AU778022B2 (en) * | 1999-07-30 | 2004-11-11 | Genentech Inc. | Charged filtration membranes and uses therefor |
EP1254666A4 (en) | 1999-12-28 | 2004-12-22 | Chugai Pharmaceutical Co Ltd | STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS |
CA2405701A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050249735A1 (en) | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
US20060018907A1 (en) | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
US20030012786A1 (en) | 2001-05-25 | 2003-01-16 | Teoh Leah S. | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients |
CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
DK1441589T3 (da) | 2001-11-08 | 2012-08-06 | Abbott Biotherapeutics Corp | Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer |
DE60231651D1 (de) * | 2001-12-21 | 2009-04-30 | Immunex Corp | Proteinreinigungsverfahren |
JP4460302B2 (ja) * | 2002-02-05 | 2010-05-12 | ジェネンテック インコーポレイテッド | タンパク質精製法 |
US20030161828A1 (en) | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
PT1501369E (pt) * | 2002-04-26 | 2015-09-21 | Genentech Inc | Purificação de proteínas com base na não afinidade |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
CN102764436A (zh) | 2002-07-19 | 2012-11-07 | 艾博特生物技术有限公司 | TNF α相关疾病的治疗 |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
DK1578774T3 (da) | 2002-09-18 | 2014-02-03 | Danisco Us Inc | Oprensning af immunoglobuliner |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
US20040162414A1 (en) | 2002-11-22 | 2004-08-19 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
PT1601697E (pt) | 2003-02-28 | 2007-09-04 | Lonza Biologics Plc | Purificação de anticorpos através de proteína a e cromatografia de troca iónica. |
WO2004098578A2 (en) | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 |
EP1697355A2 (en) | 2003-12-23 | 2006-09-06 | Axys Pharmaceuticals, Inc. | Amidino compounds as cysteine protease inhibitors |
AU2005216847B2 (en) * | 2004-02-27 | 2010-04-01 | Cytiva Bioprocess R&D Ab | A process for the purification of antibodies |
CN1234725C (zh) * | 2004-04-07 | 2006-01-04 | 陈志南 | 一种高效快速纯化制备片段抗体的方法 |
TWI556829B (zh) | 2004-04-09 | 2016-11-11 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
CN1299370C (zh) | 2004-09-21 | 2007-02-07 | 清华大学 | 球形氢氧化镍表面包覆掺杂金属M的α-Co(OH)2的方法 |
WO2006041970A2 (en) | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
RU2389552C2 (ru) * | 2004-10-21 | 2010-05-20 | Джи-И Хелткер Байо-Сайенсиз АБ | Способ очистки антител |
JP2008535913A (ja) | 2005-04-11 | 2008-09-04 | メダレックス インコーポレーティッド | タンパク質精製方法 |
TWI399384B (zh) | 2005-05-16 | 2013-06-21 | Abbott Biotech Ltd | TNFα抑制劑於治療侵蝕型多發性關節炎之用途 |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
GB2430883B (en) | 2005-09-30 | 2008-03-19 | Cambridge Antibody Tech | Interleukin-13 antibody composition |
CN101663048A (zh) | 2005-11-01 | 2010-03-03 | 艾博特生物技术有限公司 | 使用生物标志物诊断强直性脊柱炎的方法和组合物 |
KR20150064254A (ko) | 2006-04-05 | 2015-06-10 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2012586A4 (en) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
US20090317399A1 (en) | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
TWI542374B (zh) * | 2006-06-30 | 2016-07-21 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
MX2009002748A (es) | 2006-09-13 | 2009-03-26 | Abbott Lab | Mejoras de cultivos celulares. |
KR20150002896A (ko) * | 2006-10-27 | 2015-01-07 | 애브비 바이오테크놀로지 리미티드 | 결정형 항-hTNF알파 항체 |
EP2679995A1 (en) | 2007-05-31 | 2014-01-01 | AbbVie Inc. | Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders |
WO2008150490A2 (en) | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
WO2009011782A2 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
CN101980722A (zh) * | 2007-08-08 | 2011-02-23 | 雅培制药有限公司 | 结晶抗体的组合物和方法 |
MX2010002269A (es) | 2007-08-28 | 2010-03-25 | Abbott Biotech Ltd | Composiciones y metodos que comprenden proteinas de union para adalimumab. |
CN101969971A (zh) | 2007-11-30 | 2011-02-09 | 雅培制药有限公司 | 蛋白制剂及其制备方法 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
WO2009086550A1 (en) | 2008-01-03 | 2009-07-09 | Abbott Laboratories | Predicting long-term efficacy of a compound in the treatment of psoriasis |
EP2784089A1 (en) | 2008-01-15 | 2014-10-01 | AbbVie Inc. | Improved mammalian expression vectors and uses thereof |
CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
CA2717905A1 (en) | 2008-03-24 | 2009-10-01 | Abbott Biotechnology Ltd. | Methods and compositions for treating bone loss |
EP2424594A4 (en) * | 2009-04-29 | 2014-12-24 | Abbvie Biotechnology Ltd | AUTOMATIC INJECTION DEVICE |
RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
AU2010257273B2 (en) | 2009-12-24 | 2014-06-05 | Jebson, Richard Selwyn | Walking and pickup stick |
CA2789168A1 (en) | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor |
PT2575884T (pt) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Utilizações e composições para o tratamento de hidradenite supurativa (hs) |
-
2007
- 2007-04-04 KR KR1020157014516A patent/KR20150064254A/ko not_active Application Discontinuation
- 2007-04-04 EP EP13188107.0A patent/EP2738179A1/en not_active Withdrawn
- 2007-04-04 KR KR1020147036381A patent/KR20150006085A/ko not_active Application Discontinuation
- 2007-04-04 CN CN201310142761.6A patent/CN103509116A/zh active Pending
- 2007-04-04 CA CA002647029A patent/CA2647029A1/en not_active Abandoned
- 2007-04-04 SG SG10201406358SA patent/SG10201406358SA/en unknown
- 2007-04-04 NZ NZ596517A patent/NZ596517A/xx unknown
- 2007-04-04 TW TW096112211A patent/TWI392684B/zh active
- 2007-04-04 KR KR1020087024322A patent/KR20090005315A/ko active Application Filing
- 2007-04-04 EP EP16156782.1A patent/EP3088410A3/en not_active Withdrawn
- 2007-04-04 MX MX2008012896A patent/MX2008012896A/es active IP Right Grant
- 2007-04-04 CA CA2911000A patent/CA2911000A1/en not_active Abandoned
- 2007-04-04 NZ NZ611859A patent/NZ611859A/en unknown
- 2007-04-04 US US11/732,918 patent/US7863426B2/en active Active
- 2007-04-04 CN CN2012103014312A patent/CN102887955A/zh active Pending
- 2007-04-04 SG SG201102430-4A patent/SG170837A1/en unknown
- 2007-04-04 JP JP2009504272A patent/JP2009532474A/ja not_active Withdrawn
- 2007-04-04 KR KR1020147011232A patent/KR20140071452A/ko active Search and Examination
- 2007-04-04 EP EP07754818A patent/EP2004689A4/en not_active Ceased
- 2007-04-04 EP EP13188102.1A patent/EP2738178A1/en not_active Withdrawn
- 2007-04-04 RU RU2008143356/15A patent/RU2466740C2/ru active
- 2007-04-04 NZ NZ571479A patent/NZ571479A/xx unknown
- 2007-04-04 CN CN200780019220.7A patent/CN101454025B/zh active Active
- 2007-04-04 CN CN201110327798.7A patent/CN102391358B/zh not_active Ceased
- 2007-04-04 TW TW102101685A patent/TW201333030A/zh unknown
- 2007-04-04 AU AU2007235484A patent/AU2007235484B2/en active Active
- 2007-04-04 NZ NZ610566A patent/NZ610566A/en unknown
- 2007-04-04 WO PCT/US2007/008359 patent/WO2007117490A2/en active Application Filing
- 2007-04-04 BR BRPI0709726-3A patent/BRPI0709726A2/pt active Search and Examination
-
2008
- 2008-09-21 IL IL194236A patent/IL194236A/en active IP Right Grant
- 2008-10-01 ZA ZA2008/08372A patent/ZA200808372B/en unknown
-
2010
- 2010-09-15 US US12/882,601 patent/US8231876B2/en active Active
-
2012
- 2012-06-25 US US13/532,511 patent/US20130028903A1/en not_active Abandoned
- 2012-08-14 RU RU2012134840/15A patent/RU2012134840A/ru not_active Application Discontinuation
- 2012-11-21 JP JP2012255474A patent/JP5813618B2/ja active Active
-
2013
- 2013-06-26 US US13/927,576 patent/US8883156B2/en active Active
- 2013-06-26 US US13/927,236 patent/US8916153B2/en active Active
- 2013-08-01 US US13/957,006 patent/US8895009B2/en active Active
- 2013-08-02 US US13/957,679 patent/US8906372B2/en active Active
- 2013-12-06 JP JP2013252725A patent/JP5997128B2/ja active Active
-
2014
- 2014-11-21 US US14/550,606 patent/US9102723B2/en active Active
- 2014-11-21 US US14/550,809 patent/US9096666B2/en active Active
-
2015
- 2015-07-10 US US14/796,779 patent/US9273132B2/en active Active
- 2015-07-21 JP JP2015143625A patent/JP5947427B2/ja active Active
- 2015-08-31 US US14/841,474 patent/US20150361169A1/en not_active Abandoned
- 2015-08-31 US US14/841,439 patent/US9328165B2/en active Active
- 2015-09-15 JP JP2015181443A patent/JP5994004B2/ja active Active
-
2016
- 2016-06-07 US US15/175,752 patent/US20170136122A1/en not_active Abandoned
- 2016-08-24 JP JP2016163422A patent/JP6367277B2/ja active Active
-
2017
- 2017-09-28 US US15/718,621 patent/US9913902B2/en active Active
-
2018
- 2018-07-03 JP JP2018126553A patent/JP2018172416A/ja active Pending
- 2018-11-08 US US16/184,374 patent/US11083792B2/en active Active
-
2021
- 2021-02-09 US US17/171,804 patent/US20210260186A1/en not_active Abandoned
- 2021-12-15 US US17/551,515 patent/US20220339284A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016029060A5 (ja) | ||
Mehmood et al. | Fungal quorum-sensing molecules and inhibitors with potential antifungal activity: a review | |
Huang | Regulation of phenotypic transitions in the fungal pathogen Candida albicans | |
EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
NZ629204A (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
MY158663A (en) | Fermentation broth formulations | |
WO2015089183A3 (en) | System for delivery of microbial inoculants and related materials and methods | |
MA35130B1 (fr) | Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri) | |
CA2874960C (en) | Euglobulin-based method for determining the biological activity of defibrotide | |
EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
RS53408B (en) | PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION | |
WO2013096819A3 (en) | Macromolecule positioning by electrical potential | |
조준호 et al. | Enzymatic extraction of pilocarpine from Pilocarpus jaborandi | |
EA201291463A1 (ru) | Составы для инфузии лантибиотиков типа b | |
BR112014019106A8 (pt) | Composições pesticidas | |
권상운 et al. | Conducting polymer-silica composites for immobilization of enzymes | |
PE20220932A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
Youngchim | Talaromyces marneffei infection: virulence factors and rapid diagnostics | |
CN103760248A (zh) | 食品防腐剂羟基苯甲酸甲酯的检测方法 | |
WO2014118543A3 (en) | Electrochemical total protein detection system | |
RU2014114707A (ru) | ЛИОФИЛИЗИРОВАННАЯ ПИТАТЕЛЬНАЯ СРЕДА ДЛЯ ВИЗУАЛЬНОГО ВЫЯВЛЕНИЯ Ureaplasma urealyticum | |
CN105316389A (zh) | 一种复合有机酸制剂与单体酸的抑菌实验方法 | |
Kang et al. | The Inhibition Study of the Aliphatic Compounds Against Acetylcholinesterases of the Pinewood Nematode, Bursaphelenchus xylophilus | |
TH121146A (th) | สูตรผสมแอนติบอดี้ | |
UA98525C2 (en) | (2z)-(bezoylamino)(2-oxo-1,2-dihydro-3h-indole-3-ylidene)acetic acid n-r,r1-amides exhibiting nootropic activity |